There is no consensus for the role of iron chelation therapy in patients with sickle cell disease receiving blood transfusions while hospitalized. The primary objective of this study was to assess the frequency of iron overload in adult inpatients with sickle cell disease and characterize the use of inpatient intravenous iron chelation therapy at the time of red blood cell transfusion.
No takes yet. Share an insight, caveat, or question.
Nicole et al. (2018) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: